Pipeline

Our Pipeline

Our broad pipeline tackles a wide range of severe diseases in the therapeutic areas of oncology, the central nervous system (CNS), nephrology and immunology.

Oncology

Pan-KRAS

Mutation agnostic KRAS-driven solid tumors

MYC

B-ALL, Burkitt’s, Double-HIT, DLBCL, Multiple Myeloma

CNS

HTT

Huntington’s Disease

Undisclosed Target​

Amyotrophic lateral sclerosis (ALS)

Undisclosed Target​(s)

Alternative polyadenylation (APA)

Nephrology

Undisclosed Target​

High-risk genotypes for CKD

Undisclosed Target​

Focal segmental glomerulosclerosis (FSGS)

Immunology

Immuno-Oncology

Cell targeting for solid tumors

Autoimmune

Cell and tissue-targeting for Th17-mediated diseases (i.g. – psoriasis, RA, MS, IBD, Chronic GvHD)

Our Pipeline

Our broad pipeline tackles a wide range of severe diseases in the therapeutic areas of oncology, the central nervous system (CNS), nephrology and immunology.

Oncology

Pan-KRAS

Mutation agnostic KRAS-driven solid tumors

MYC

B-ALL, Burkitt’s, Double-HIT, DLBCL, Multiple Myeloma

CNS

HTT

Huntington’s Disease

Undisclosed Target​

Amyotrophic lateral sclerosis (ALS)

Undisclosed Target​(s)

Alternative polyadenylation (APA)

Nephrology

Undisclosed Target​

High-risk genotypes for CKD

Undisclosed Target​

Focal segmental glomerulosclerosis (FSGS)

Immunology

Immuno-Oncology

Cell targeting for solid tumors

Autoimmune

Cell and tissue-targeting for Th17-mediated diseases (i.g. – psoriasis, RA, MS, IBD, Chronic GvHD)

Our Pipeline

Our broad pipeline tackles a wide range of severe diseases in the therapeutic areas of oncology, the central nervous system (CNS), nephrology and immunology.

Oncology

Pan-KRAS

Mutation agnostic KRAS-driven solid tumors

MYC

B-ALL, Burkitt’s, Double-HIT, DLBCL, Multiple Myeloma

CNS

HTT

Huntington’s Disease

Undisclosed Target​

Amyotrophic lateral sclerosis (ALS)

Undisclosed Target​(s)

Alternative polyadenylation (APA)

Nephrology

Undisclosed Target​

High-risk genotypes for CKD

Undisclosed Target​

Focal segmental glomerulosclerosis (FSGS)

Immunology

Immuno-Oncology

Cell targeting for solid tumors

Autoimmune

Cell and tissue-targeting for Th17-mediated diseases (i.g. – psoriasis, RA, MS, IBD, Chronic GvHD)

Our Pipeline

Our broad pipeline tackles a wide range of severe diseases in the therapeutic areas of oncology, the central nervous system (CNS), nephrology and immunology.

Oncology

Pan-KRAS

Mutation agnostic KRAS-driven solid tumors

MYC

B-ALL, Burkitt’s, Double-HIT, DLBCL, Multiple Myeloma

CNS

HTT

Huntington’s Disease

Undisclosed Target​

Amyotrophic lateral sclerosis (ALS)

Undisclosed Target​(s)

Alternative polyadenylation (APA)

Nephrology

Undisclosed Target​

High-risk genotypes for CKD

Undisclosed Target​

Focal segmental glomerulosclerosis (FSGS)

Immunology

Immuno-Oncology

Cell targeting for solid tumors

Autoimmune

Cell and tissue-targeting for Th17-mediated diseases (i.g. – psoriasis, RA, MS, IBD, Chronic GvHD)